At a glance
ClinicalIndex Comparison RecordN/ACompleted· 24 enrolled
Drug / intervention
Pancrelipasedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
In Brief
An observational study evaluating Pancrelipase for Cystic Fibrosis and 3 related conditions. Completed, enrolled 24 participants across 21 sites.
Detailed Summary
This study aims at collecting the information related to the safety and effectiveness in the pancreatic exocrine insufficiency patients due to cystic fibrosis receiving the treatment with LipaCreon in order to evaluate the effective and safe use of LipaCreon.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis, Exocrine Pancreatic Insufficiency, Pancreatic Diseases, Digestive System Diseases
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedSep 2011
Primary CompletionMar 2018
TodayJul 2026
First PostedSep 2, 2011
Enrollment StartAug 1, 2011
Primary CompletionMar 1, 2018
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 14.8 years ago
Interventions
Pancrelipasedrug